Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Prostate cancer biology helps identify hormone therapy candidates

A recent analysis of the NRG-RTOG 0534 "SPPORT" clinical trial evaluated the Luminal B (LumB) molecular subtype using the PAM50 genomic classifier to determine whether tumor biology could help identify patients most likely to benefit from hormone therapy.

27 Sep 2026

$Hypofractionated radiotherapy for prostate cancer matches conventional treatment outcomes$

Hypofractionated radiotherapy for prostate cancer matches conventional treatment outcomes

Men with high-risk prostate cancer have a higher likelihood of having residual disease following prostatectomy and may require radiation therapy after surgery, particularly when PSA levels begin to rise. Conventional postprostatectomy radiotherapy (COPORT) is typically delivered over 37 fractions, while hypofractionated postprostatectomy radiotherapy (HYPORT) delivers a slightly lower total radiation dose over just 25 fractions.

27 Sep 2026

MD Anderson researchers showcase new findings in radiation oncology at ASTRO 2026

Experts from The University of Texas MD Anderson Cancer Center will present nearly 70 abstracts at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.

25 Sep 2026

UCLA researchers present new radiation advances at ASTRO 2026

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share new research and clinical trial findings at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, including studies on new treatment approaches for prostate, bile duct and head and neck cancers, personalized radiation therapy based on genetic risk, and advances in targeted radiation and radioligand therapy designed to improve cancer control while limiting treatment side effects.

25 Sep 2026

Researchers find how prostate tumors reshape the immune microenvironment

Researchers at The University of Texas MD Anderson Cancer Center have identified a previously unknown pathway that prostate tumors leverage to suppress the immune system by reshaping the tumor microenvironment to resist treatment.

25 Sep 2026

Leica Biosystems brings Tempus pathology products to Aperio AI Store, accelerating AI-powered capabilities for oncology research

The Aperio AI Store integrates Tempus' AI applications, transforming complex pathology images into research insights and accelerating cancer diagnostics.

From Leica Biosystems 25 Sep 2026

Neuromedin U drives immune suppression in aggressive prostate cancer

A new study from The Wistar Institute has found a link between the nervous system and the rapid development of neuroendocrine prostate cancer (NEPC), an aggressive form of the disease.

24 Sep 2026

MIT researchers build cell collection device for early cancer detection

One of the main reasons that ovarian cancer is among the deadliest forms of cancer is timing: When doctors catch it early, the five-year survival rate can be north of 90 percent.

24 Sep 2026

Cancer-related DNA changes may appear in blood years before diagnosis

Researchers found that genome-wide plasma cfDNA methylation profiles collected before diagnosis contained early molecular signatures associated with future prostate and breast cancer, with prostate silencer methylation providing the stronger risk stratification. Breast enhancer signals were weaker and varied by subtype and disease stage, indicating that cfDNA methylation may have greater value for risk assessment and surveillance than as a standalone diagnostic test.

23 Sep 2026

Cancer incidence rises faster among people with type 2 diabetes

A nationwide study being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has found that people with type 2 diabetes (T2D) have a higher risk of developing cancer, with cancer incidence rising more among people with T2D than those without diabetes over the past 25 years, largely driven by obesity-related cancers.

22 Sep 2026

Scientists reveals how cancer-causing p53 mutations remain invisible to the immune system

One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see.

17 Sep 2026

Specialized imaging technique detects most clinically relevant prostate cancers

An elevated PSA level in the blood may indicate prostate cancer, but does not yet allow for a definitive diagnosis.

16 Sep 2026

New AACR report outlines future of cutting-edge cancer research

Today, the American Association for Cancer Research (AACR) released the 16th edition of its annual Cancer Progress Report.

16 Sep 2026

Study reveals processes driving DNA damage in prostate cancer

Cancer begins with errors in the DNA inside our cells, and those errors are often more complicated than a handful of mutated genes.

9 Sep 2026

New genetic map helps track aggressive prostate cancer development

Prostate cancer is the second most common form of cancer among men globally. Yet, we still know relatively little about why the disease develops or why some men live with it for years while in others it progresses aggressively.

9 Sep 2026

UCLA researchers develop scalable TCR therapy for solid tumors

T cell receptor, or TCR, therapy is a cancer treatment that genetically reprograms immune cells, called T cells, to hunt down cancer with precision. It's similar to another treatment, CAR T-cell therapy, but with one key difference: CAR T-cell therapy can only spot proteins that naturally appear outside of a cancer cell.

8 Sep 2026